Barrett Steinberg
About Barrett Steinberg
Barrett Steinberg serves as the Senior Director at Tessera Therapeutics, where he specializes in computational biology and bioengineering for therapeutic applications. He has extensive experience in gene editing and gene therapy, having held various roles in prominent biotechnology companies and academic institutions.
Current Role at Tessera Therapeutics
Barrett Steinberg serves as the Senior Director at Tessera Therapeutics. He has been in this role since 2023, contributing to the company's mission in gene editing and gene therapy. His responsibilities include overseeing research initiatives and directing teams focused on innovative platform technologies utilizing synthetic biology.
Previous Experience at Tessera Therapeutics
Steinberg has held multiple positions at Tessera Therapeutics. He was the Associate Director from 2020 to 2021 and later served as the Director of Synthetic Biology from 2021 to 2023. In these roles, he directed research teams to engineer and characterize new platform technologies, enhancing the company's capabilities in therapeutic applications.
Experience at Editas Medicine
Barrett Steinberg worked at Editas Medicine as a Scientist II in RNA and Protein Engineering from 2017 to 2018. Prior to that, he held the position of Scientist I in the same department from 2015 to 2017. His work focused on advancing RNA and protein engineering, contributing to the development of gene editing technologies.
Educational Background
Steinberg earned his Doctor of Philosophy (Ph.D.) in Chemical and Biomolecular Engineering from The Johns Hopkins University, where he was a Ph.D. candidate from 2010 to 2015. He also holds a Bachelor of Science (B.S.) in Biomedical Engineering from Boston University, which he completed from 2006 to 2010.
Specialization and Research Focus
Barrett Steinberg specializes in computational biology and bioengineering, particularly for therapeutic applications. His research emphasizes fundamental discoveries in gene editing and gene therapy, aligning with his leadership roles in various biotechnology companies.